Product Code: 139288-08-22
Acquired von Willebrand syndrome is a highly heterogeneous bleeding disorder, usually displays mild to moderate hemorrhagic symptoms that may at times be severe too. Many a time the severity increases post-surgery. AvWS is considered as a rare disorder, however, the actual prevalence is not as rare. In case the laboratory findings diagnoses vWD in a patient with no family history, AvWD associated conditions is usually explored. The acquired von willebrand disease treatment market is anticipated to grow, at a CAGR of 5.86% during the forecast period of 2022 to 2030.
Diagnosis Remains as The Largest Challenge
AvWD screening becomes crucial in patients with onco-hematologic disorders, patients who experienced unexplained bleeding, or before undergoing any invasive procedure. The acquired von Willebrand disease prevalence represents about 1% to 5% of all von Willebrand disease. Its prevalence is higher in certain groups. For example, it has been reported up to 20% of malignancies, and up to 100% of certain high flow states such as extracorporeal membrane oxygenation (ECMO) and metallic cardiac valves. The diagnostic complexity and milder form of AvWS without symptoms make it difficult to finalize on the actual prevalence rate of AvWD.
Increasing Support of Governments Led by Increasing Awareness of AvWS
The demand for the AvWD treatment market has increased as governments across the globe have become increasingly aware of the von Willebrand syndrome and its associated treatment. The treatment for this condition varies across countries. Hpwever, one of the significant driver impacting the market revenues is rising prevalence of bleeding disorders especially acquired bleeding disorders. Von Willebrand disease is a fairly prevalent bleeding disorder, according to the World Federation of Hemophilia. Von Willebrand disease is caused by a deficiency in the protein known as the Von Willebrand factor, which is present in the blood.
Desmopressin records the highest revenues
In the year 2021, Desmopressin recorded the highest revenues in comparison to the other drugs. Desmopressin remains as the first line therapy for AvWD and is proven to be efficient for patients with mild symptoms. Easy accessibility of Desmopressin across the globe and availability of Desmopressin through different routes of drug administration such as injection, tablet and intranasal spray remains as the key driver for the dominance of this market segment.
Injections Remained as Dominant Form Among Route of Drug Administration
In the year 2021, Injection as a mode of AvWD drug administration dominated the market segment with revenues of about $ 20,880 thousand. Major AvWD treatment drugs are administered through injections and infusions. Primary drug Desmopressin is widely administered through injections, similarly replacement therapies are also administered through this route. Injections respond very quickly during emergency and are very effective mode of drug administration. Therefore, the market is also expected to grow at the fastest pace during the forecast period.
North America Dominates In terms of Market Revenues
North America was observed as the largest market for AvWD treatment in 2021. North America dominated the market due to its aging population, supportive government policies, high awareness associated with hemophilia and types in people, and developed healthcare infrastructure. Asia Pacific was observed as the attractive market for AvWS treatment due to its emerging healthcare infrastructure, high disposable income, transforming government policies specific to orphan diseases diagnosis and treatment, and rising public awareness associated with healthcare insurance and disease diagnosis. The key players in the acquired AvWS treatment market are Novo Nordisk A/S, Genentech, Inc., F. Hoffman-La Roche AG, Sanofi SA, and others.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Acquired von Willebrand Disease (AvWD) Treatment market are as follows:
- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
Micro and macro environment factors that are currently influencing the Acquired von Willebrand Disease (AvWD) Treatment market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
- Treatment Type
- Desmopressin
- Replacement Therapy
- Clot-stabilizing Medications/anti-fibrinolytic medications
- Others
- Route of Drug Administration
- Oral
- Injection
- Others
- Healthcare Settings
- Hospitals
- Clinics
- Others
- Region Segment (2020-2030; US$ Million)
- North America
- U.S.
- Canada
- Rest of North America
- UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa
- Global Impact of Covid-19 Segment (2020-2021; US$ Million )
- Pre Covid-19 situation
- Post Covid-19 situation
Key questions answered in this report:
- What are the key micro and macro environmental factors that are impacting the growth of Acquired von Willebrand Disease (AvWD) Treatment market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Acquired von Willebrand Disease (AvWD) Treatment market?
- Which is the largest regional market for Acquired von Willebrand Disease (AvWD) Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Acquired von Willebrand Disease (AvWD) Treatment market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Acquired von Willebrand Disease (AvWD) Treatment market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Acquired von Willebrand Disease (AvWD) Treatment Market
- 2.2. Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Treatment Type, 2021 (US$ Million)
- 2.3. Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Replacement Therapy, 2021 (US$ Million)
- 2.4. Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Route of Drug Administration, 2021 (US$ Million)
- 2.5. Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Healthcare Settings, 2021 (US$ Million)
- 2.6. Global Acquired von Willebrand Disease (AvWD) Treatment Market, By Geography, 2021 (US$ Million)
- 2.7. Impact of Covid 19
- 2.8. Attractive Investment Proposition by Geography, 2021
- 2.9. Competitive Analysis
- 2.9.1. Market Positioning of Key Acquired von Willebrand Disease (AvWD) Treatment Market Vendors
- 2.9.2. Strategies Adopted by Acquired von Willebrand Disease (AvWD) Treatment Market Vendors
- 2.9.3. Key Industry Strategies
- 2.9.4. Tier Analysis 2021 Versus 2030
- 2.10. Key Buying Criteria
- 2.11. Key Case Reports
- 2.12. Scenario Analysis
- 2.12.1. Optimistic estimates and analysis
- 2.12.2. Realistic estimates and analysis
- 2.12.3. Pessimistic estimates and analysis
- 2.13. Market Profiling
- 2.14. Sales and Marketing Plan
- 2.15. Top Market Conclusions
- 2.16. Strategic Recommendations
3. Acquired von Willebrand Disease (AvWD) Treatment Market: Business Outlook & Market Dynamics
- 3.1. Introduction
- 3.2. Global Acquired von Willebrand Disease (AvWD) Treatment Market Value, 2020 - 2030, (US$ Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers
- 3.3.2. Market Restraints
- 3.3.3. Key Challenges
- 3.3.4. Key Opportunities
- 3.4. Impact Analysis of Drivers and Restraints
- 3.5. See-Saw Analysis
- 3.6. Porter's Five Force Model
- 3.6.1. Supplier Power
- 3.6.2. Buyer Power
- 3.6.3. Threat Of Substitutes
- 3.6.4. Threat Of New Entrants
- 3.6.5. Competitive Rivalry
- 3.7. PESTEL Analysis
- 3.7.1. Political Landscape
- 3.7.2. Economic Landscape
- 3.7.3. Technology Landscape
- 3.7.4. Legal Landscape
- 3.7.5. Social Landscape
- 3.8. Heptalysis Analysis
- 3.9. Critical Investigation of Business Problems Through Five Whys Root Cause Analysis & Relevant Solutions
4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 4.1. Market Overview
- 4.2. Growth & Revenue Analysis: 2021 Versus 2030
- 4.3. Market Segmentation
5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2021 Versus 2030
- 5.3. Market Segmentation
- 5.3.1. Clot-stabilizing Medications/anti-fibrinolytic medications
- 5.3.2. Others
6. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2021 Versus 2030
- 6.3. Market Segmentation
- 6.3.1. Oral
- 6.3.2. Injection
- 6.3.3. Others
7. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 7.1. Market Overview
- 7.2. Growth & Revenue Analysis: 2021 Versus 2030
- 7.3. Market Segmentation
- 7.3.1. Hospitals
- 7.3.2. Clinics
- 7.3.3. Others
8. North America Acquired von Willebrand Disease (AvWD) Treatment Market, 2020-2030, USD (Million)
- 8.1. Market Overview
- 8.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 8.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 8.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 8.5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 8.6.Acquired von Willebrand Disease (AvWD) Treatment Market: By Region, 2020-2030, USD (Million)
- 8.6.1.North America
- 8.6.1.1. U.S.
- 8.6.1.1.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 8.6.1.1.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 8.6.1.1.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 8.6.1.1.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 8.6.1.2. Canada
- 8.6.1.2.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 8.6.1.2.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 8.6.1.2.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 8.6.1.2.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 8.6.1.3. Rest of North America
- 8.6.1.3.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 8.6.1.3.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 8.6.1.3.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 8.6.1.3.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
9. UK and European Union Acquired von Willebrand Disease (AvWD) Treatment Market, 2020-2030, USD (Million)
- 9.1. Market Overview
- 9.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 9.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 9.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 9.5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 9.6.Acquired von Willebrand Disease (AvWD) Treatment Market: By Region, 2020-2030, USD (Million)
- 9.6.1.UK and European Union
- 9.6.1.1. UK
- 9.6.1.1.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 9.6.1.1.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 9.6.1.1.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 9.6.1.1.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 9.6.1.2. Germany
- 9.6.1.2.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 9.6.1.2.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 9.6.1.2.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 9.6.1.2.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 9.6.1.3. Spain
- 9.6.1.3.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 9.6.1.3.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 9.6.1.3.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 9.6.1.3.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 9.6.1.4. Italy
- 9.6.1.4.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 9.6.1.4.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 9.6.1.4.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 9.6.1.4.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 9.6.1.5. France
- 9.6.1.5.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 9.6.1.5.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 9.6.1.5.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 9.6.1.5.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 9.6.1.6. Rest of Europe
- 9.6.1.6.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 9.6.1.6.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 9.6.1.6.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 9.6.1.6.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
10. Asia Pacific Acquired von Willebrand Disease (AvWD) Treatment Market, 2020-2030, USD (Million)
- 10.1. Market Overview
- 10.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 10.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 10.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 10.5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 10.6.Acquired von Willebrand Disease (AvWD) Treatment Market: By Region, 2020-2030, USD (Million)
- 10.6.1.Asia Pacific
- 10.6.1.1. China
- 10.6.1.1.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 10.6.1.1.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 10.6.1.1.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 10.6.1.1.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 10.6.1.2. Japan
- 10.6.1.2.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 10.6.1.2.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 10.6.1.2.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 10.6.1.2.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 10.6.1.3. India
- 10.6.1.3.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 10.6.1.3.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 10.6.1.3.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 10.6.1.3.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 10.6.1.4. Australia
- 10.6.1.4.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 10.6.1.4.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 10.6.1.4.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 10.6.1.4.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 10.6.1.5. South Korea
- 10.6.1.5.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 10.6.1.5.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 10.6.1.5.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 10.6.1.5.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 10.6.1.6. Rest of Asia Pacific
- 10.6.1.6.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 10.6.1.6.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 10.6.1.6.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 10.6.1.6.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
11. Latin America Acquired von Willebrand Disease (AvWD) Treatment Market, 2020-2030, USD (Million)
- 11.1. Market Overview
- 11.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 11.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 11.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 11.5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 11.6.Acquired von Willebrand Disease (AvWD) Treatment Market: By Region, 2020-2030, USD (Million)
- 11.6.1.Latin America
- 11.6.1.1. Brazil
- 11.6.1.1.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 11.6.1.1.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 11.6.1.1.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 11.6.1.1.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 11.6.1.2. Mexico
- 11.6.1.2.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 11.6.1.2.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 11.6.1.2.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 11.6.1.2.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 11.6.1.3. Rest of Latin America
- 11.6.1.3.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 11.6.1.3.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 11.6.1.3.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 11.6.1.3.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
12. Middle East and Africa Acquired von Willebrand Disease (AvWD) Treatment Market, 2020-2030, USD (Million)
- 12.1. Market Overview
- 12.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 12.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 12.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 12.5. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 12.6.Acquired von Willebrand Disease (AvWD) Treatment Market: By Region, 2020-2030, USD (Million)
- 12.6.1.Middle East and Africa
- 12.6.1.1. GCC
- 12.6.1.1.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 12.6.1.1.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 12.6.1.1.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 12.6.1.1.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 12.6.1.2. Africa
- 12.6.1.2.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 12.6.1.2.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 12.6.1.2.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 12.6.1.2.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
- 12.6.1.3. Rest of Middle East and Africa
- 12.6.1.3.1. Acquired von Willebrand Disease (AvWD) Treatment Market: By Treatment Type, 2020-2030, USD (Million)
- 12.6.1.3.2. Acquired von Willebrand Disease (AvWD) Treatment Market: By Replacement Therapy, 2020-2030, USD (Million)
- 12.6.1.3.3. Acquired von Willebrand Disease (AvWD) Treatment Market: By Route of Drug Administration, 2020-2030, USD (Million)
- 12.6.1.3.4. Acquired von Willebrand Disease (AvWD) Treatment Market: By Healthcare Settings, 2020-2030, USD (Million)
13. Company Profile
- 13.1. Baxter Healthcare Corporation
- 13.1.1. Company Overview
- 13.1.2. Financial Performance
- 13.1.3. Product Portfolio
- 13.1.4. Strategic Initiatives
- 13.2. Biogen
- 13.2.1. Company Overview
- 13.2.2. Financial Performance
- 13.2.3. Product Portfolio
- 13.2.4. Strategic Initiatives
- 13.3. Pfizer
- 13.3.1. Company Overview
- 13.3.2. Financial Performance
- 13.3.3. Product Portfolio
- 13.3.4. Strategic Initiatives
- 13.4. F. HOFFMAN LA ROCHE
- 13.4.1. Company Overview
- 13.4.2. Financial Performance
- 13.4.3. Product Portfolio
- 13.4.4. Strategic Initiatives
- 13.5. Sanofi
- 13.5.1. Company Overview
- 13.5.2. Financial Performance
- 13.5.3. Product Portfolio
- 13.5.4. Strategic Initiatives
- 13.6. Ferring Pharmaceuticals
- 13.6.1. Company Overview
- 13.6.2. Financial Performance
- 13.6.3. Product Portfolio
- 13.6.4. Strategic Initiatives
- 13.7. Genentech, Inc.
- 13.7.1. Company Overview
- 13.7.2. Financial Performance
- 13.7.3. Product Portfolio
- 13.7.4. Strategic Initiatives
- 13.8. Bristol Myers Squibb
- 13.8.1. Company Overview
- 13.8.2. Financial Performance
- 13.8.3. Product Portfolio
- 13.8.4. Strategic Initiatives
- 13.9. Novo Nordisk
- 13.9.1. Company Overview
- 13.9.2. Financial Performance
- 13.9.3. Product Portfolio
- 13.9.4. Strategic Initiatives
- 13.10. GlaxoSmithKline plc
- 13.10.1. Company Overview
- 13.10.2. Financial Performance
- 13.10.3. Product Portfolio
- 13.10.4. Strategic Initiatives
- 13.11. Takeda Pharmaceutical
- 13.11.1. Company Overview
- 13.11.2. Financial Performance
- 13.11.3. Product Portfolio
- 13.11.4. Strategic Initiatives
- 13.12. CSL Behring
- 13.12.1. Company Overview
- 13.12.2. Financial Performance
- 13.12.3. Product Portfolio
- 13.12.4. Strategic Initiatives
- 13.13. Bayer AG
- 13.13.1. Company Overview
- 13.13.2. Financial Performance
- 13.13.3. Product Portfolio
- 13.13.4. Strategic Initiatives